800+ Tri-State Real Estate Principals, Placemakers & Developers to Gather in 1 Weeks to Discuss Jersey City and Metro NYC. Hear about Opportunity Zones, Economic Development, Placemaking, Affordable Housing, Retail, Emerging Neighborhoods & the Investment
ASTOR CAPITAL PLANS $45 M CLEAN ENERGY INITIATIVE The Astor Capital Fund, Alternate Energy group announces an $45M Commitment to Energy Investing --
NEW YORK & SAN FRANCISCO & HONG KONG & CHICAGO - -- Astor Capital Fund's alternate energy group announced on Tuesday, that the company is in talks to roll out and commit an additional $45M in a new clean energy investment initiative. While many banks...
VALFIX Medical Announces Issuance of Second U.S. Patent for Its Heart Valve Repair and Replacement Technology
TEL AVIV, Israel - -- VALFIX Medical Ltd. is pleased to announce the issuance of US Patent No. 10,463,486 issued November 5th, 2019. This is the second US patent granted for VALFIX and was approved only 2 years and 9 months since its priority date. This..
NEW YORK - -- In his first-ever video appearance, Satoshi Nakamoto speaks about his creation of Bitcoin and why he has ended his anonymity to restore his original vision for cryptocurrency and block chain technology.
University of Illinois at Urbana – Champaign and RCM-X deliver top technology for student development
RCM-X, the trading technology subsidiary of RCM Alternatives, and University of Illinois at Urbana – Champaign announced the implementation of RCM-X's state-of-the-art strategy development software in the trading technology lab at Illinois.
STEAMBOAT SPRINGS, Colo. - -- Home-grown Steamboat-based prefab building company, SmartPads LLC, is gaining fast traction throughout Colorado since opening for business in 2018, with sales closing in Leadville, Nathrop, Winter Park, Steamboat Springs...
Dubbed as "The Most Exciting & Energetic Domestic Emerging Market". 975 Tri-State Principals, Placemakers & Developers to Gather in 3 Weeks to Discuss Jersey City and the Metro NYC Market. Hear from Investors, Innovators & Stakeholders about Economic Deve
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PHILADELPHIA - -- SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).